Restricting FISH testing to the subset of GCB-type DLBCL with MYC and BCL2 co-expression has been proposed as a cost-effective approach for identifying high-risk patients [14]; however, this strategy would fail to identify roughly one-third of all DH/TH lymphomas [74]. This evidence concerns the gene MYC and lymphoma.